Eisai to Unveil Promising Four-Year Data on Lecanemab at Alzheimer’s Association International Conference 2025
Tokyo, Japan and Woodcliff Lake, NJ, USA – July 21, 2025 – Eisai Co., Ltd. and Eisai Inc. today announced with great anticipation that they will present pivotal four-year efficacy and safety data on the continuous treatment with lecanemab (Leqembi®) at the upcoming Alzheimer’s Association International Conference (AAIC) 2025. The presentation, scheduled for July 21st, 2025, will offer invaluable insights into the long-term impact of this groundbreaking therapy for individuals living with early Alzheimer’s disease.
This significant presentation at one of the world’s premier gatherings for Alzheimer’s research underscores Eisai’s unwavering commitment to advancing the understanding and treatment of this debilitating neurodegenerative condition. The four-year data will build upon the existing body of evidence for lecanemab, a humanized antibody that selectively targets soluble and insoluble aggregated forms of amyloid-beta (Aβ) protofibrils, a neurotoxic species of Aβ considered to be one of the drivers of Alzheimer’s pathology.
The AAIC is renowned for bringing together leading scientists, clinicians, and researchers from across the globe to share the latest discoveries and foster collaboration in the fight against Alzheimer’s disease. Eisai’s presentation of these extended data points to a continued dedication to rigorous scientific evaluation and a thorough exploration of lecanemab’s potential for sustained benefit in patients.
While specific details of the data to be presented have not yet been disclosed, the focus on four-year outcomes suggests a comprehensive analysis of lecanemab’s impact on both cognitive and functional measures, as well as its long-term safety profile. Such long-term data is crucial for understanding the durability of treatment effects and for informing clinical practice and patient management strategies.
Eisai has been at the forefront of Alzheimer’s disease research, striving to develop therapies that not only address the underlying pathology but also offer meaningful improvements in the lives of patients and their families. The presentation of these four-year findings at AAIC 2025 is a testament to this enduring mission.
Further details regarding the presentation, including the specific session and time, will be made available closer to the conference dates through the Alzheimer’s Association’s official channels. This upcoming presentation represents an important milestone in the ongoing journey to combat Alzheimer’s disease, and the global scientific community eagerly awaits the insights that Eisai will share.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025’ at 2025-07-21 23:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.